William Shapiro, MD
Pulmonary Disease · Philadelphia, PANPI 1609130947
Payments from drug & device makers
Across 14 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$73
- Philips North America LLC$72
- Genentech USA, Inc.$40
- Nabriva Therapeutics, PLC$24
- Cardinal Health 200 LLC$18
- Fisher & Paykel Healthcare Inc$18
- plus $49 from 3 others
What the payments were for
- Food & beverage$294100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 2 | $73 |
| Philips North America LLC | 4 | $72 |
| Genentech USA, Inc. | 2 | $40 |
| Nabriva Therapeutics, PLC | 1 | $24 |
| Cardinal Health 200 LLC | 1 | $18 |
| Fisher & Paykel Healthcare Inc | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Resmed Corp | 1 | $16 |
How this compares
$294 in reported general payments places this provider in the 25th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 25 | $329,495 |
| UptraviSelexipag | 13 | $297,794 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $61,196 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $20,420 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $19,570 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $15,589 |
| Ambrisentan | 11 | $13,579 |
| EliquisApixaban | 11 | $11,118 |
| Spiriva RespimatTiotropium Bromide | 16 | $8,312 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $8,254 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $7,026 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 40 | $6,392 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $5,445 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 107 | $3,346 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $2,540 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$18.2M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Steven KelsenPhiladelphia$847K
- Parth RaliPhiladelphia$814K
- Kartik ShenoyPhiladelphia$701K
- Christopher ManleyPhiladelphia$580K
- Michaela AndersonPhiladelphia$515K
- Michael BaramPhiladelphia$501K
- Ross SummerPhiladelphia$483K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.